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Background: Exacerbations of COPD are frequent and commonly triggered by respiratory 
tract infections. The purpose of our study was to investigate innate immunity in stable COPD 
patients.
Methods: Induced sputum was collected from 51 stable consecutive COPD patients recruited 
from the COPD Clinic of CHU Liege and 35 healthy subjects. Expression of interferons beta 
(IFN-β) and lambda1 (IL-29), IFN-stimulated genes (ISGs) MxA, OAS, and viperin were mea-
sured in total sputum cells by reverse transcription quantitative polymerase chain reaction (RT-
qPCR). The presence of Picornaviruses was assessed by RT-PCR, while potential pathogenic 
microorganisms (PPM) were identified by sputum bacteriology.
Results: Expression of IL-29 was found in 16 of 51 COPD patients (31%) and in nine of 35 
healthy subjects (26%), while IFN-β was detected in six of 51 COPD patients (12%) and in two 
of 35 healthy subjects (6%). ISGs were easily detectable in both groups. In the whole group of 
COPD patients, OAS expression was decreased (P,0.05), while that of viperin was increased 
(P,0.01) compared to healthy subjects. No difference was found with respect to MxA. COPD 
patients from group D of Global Initiative for Chronic Obstructive Lung Disease (GOLD) had 
reduced expression of all three ISGs (P,0.01 for MxA, P,0.05 for OAS, and P,0.01 for 
viperin) as compared to those of group B patients. Picornaviruses were detected in eight of 
51 (16%) COPD patients vs four of 33 (12%) healthy subjects, while PPM were detected in 
seven of 39 (18%) COPD patients and associated with raised sputum neutrophil counts. IFN-β 
expression was raised when either picornavirus or PPM were detected (P=0.06), but no differ-
ence was seen regarding IL-29 or ISGs.
Conclusion: ISGs expression was reduced in severe COPD that may favor exacerbation and 
contribute to disease progress by altering response to infection.
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Background
COPD is a preventable and treatable disease characterized by persistent airflow 
limitation that is usually progressive.1 COPD is currently the fourth leading cause of 
morbidity and mortality worldwide and its prevalence is projected to increase in the 
coming decades because of continuous exposure to COPD risk factors (eg, tobacco 
smoke and smoke from biomass fuels) and population aging.2
Episodes of respiratory symptom worsening frequently occur in COPD, and these 
exacerbations are commonly triggered by respiratory tract viral or bacterial infections. 
Viruses have been detected in 47%–56% of the patients in exacerbation and approxi-
mately half of them are rhinoviruses,3 while bacteria are assumed to be the cause of 
50% of exacerbations.4 In addition, coinfection with viruses and bacteria account for 
~26% of hospitalized COPD exacerbations.5,6
Correspondence: Clarissa hilzendeger
Department of respiratory Medicine, 
Centre hospitalier Universitaire (ChU) 
liege, groupe Interdisciplinaire de 
génoprotéomique appliquée (gIga) I3 
University of liege, sart-Tilman, Bat B35, 
4000 liege, Belgium
Tel +32 43 66 4916
email c.hilzendeger@student.ulg.ac.be 
Journal name: International Journal of COPD
Article Designation: Original Research
Year: 2016
Volume: 11
Running head verso: Hilzendeger et al
Running head recto: Reduced sputum ISGs in severe COPD
DOI: http://dx.doi.org/10.2147/COPD.S105948
International Journal of COPD 2016:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1486
hilzendeger et al
Airway and lung inflammation is central in COPD,7 but 
there are contradictory data regarding the innate immunity 
in COPD. One study using primary bronchial epithelial cells 
infected in vitro with rhinovirus-1B showed that COPD cells 
had higher expression of interleukin (IL)-6 and interferons 
(IFNs)-β and λ1 in comparison to healthy controls.8 In 
addition, IL-8 was found to be increased in sputum from 
COPD patients when compared to healthy subjects.9–12 
On the other hand, reduced IL-8 production was described 
in COPD-diseased human bronchial/tracheal epithelial cells 
treated with cigarette smoke condensate,13 as well as in 
alveolar macrophages from COPD patients incubated with 
respiratory pathogens.14
The study of Mallia et al with experimental rhinovirus 
infection in healthy subjects and COPD patients showed that 
COPD subjects had increased symptoms, airway obstruction, 
and inflammation with raised sputum neutrophils and proin-
flammatory cytokine IL-8 production as compared to healthy 
subjects.15 They also showed that bronchoalveolar lavage 
cells from COPD patients produced less IFN-β in response to 
viral infection in vitro. Interferons and their stimulated genes 
play a major role in defense against infectious agents.16,17 
Much less is known regarding mechanisms of virus-induced 
exacerbations in COPD compared to asthma,18 and there are 
limited data on the expression of IFNs and their stimulated 
genes in stable COPD.
The purpose of our study was to investigate the innate 
antiviral immunity in stable COPD patients suffering from 
variable disease severity. To this end, we have assessed 
gene expression of IFN-β and IFN-λ1 (IL-29) in sputum 
cells from 51 stable COPD and 35 healthy subjects. We 
have also extended our analysis to several IFN-stimulated 
genes (ISGs) supposed to mediate the cellular response to 
IFN by assessing three genes involved at different steps of 
intracellular viral cycle. MxA forms oligomers that trap viral 
components at early time points of the cellular infection, 
while OAS activates the latent form of RNaseL leading to 
viral and host RNA degradation.19 Viperin exerts its effects 
at the later stages of this life cycle by preventing the release 
of viral particles apparently by disrupting lipid droplets.20
Methods
subject characteristics and study design
The study was performed with subjects recruited from the 
Ambulatory Clinic of CHU Liege. Patient characteristics 
are given in Table 1. Diagnosis of COPD was performed 
according to the Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) criteria:1 post-bronchodilator 
(400 µg salbutamol) forced expiratory volume in 1 second 
(FEV
1
)/forced vital capacity (FVC) ratio ,70% in patients 
who presented dyspnea, chronic cough or sputum produc-
tion, and a history of exposure to risk factors for the disease 
(tobacco smoke, occupational dusts or chemicals) with all 
subjects reporting a smoking history of at last 10 pack-year. 
On the day of the visit, COPD patients completed the COPD 
assessment test (CAT questionnaire)21 and were asked about 
the number of exacerbations in the previous year as defined 
by an intake of antibiotic and/or methylprednisolone for at 
least 3 days for worsening of respiratory symptoms. Patients 
were divided in four groups according to GOLD classification 
of airway obstruction severity based on post-bronchodilation 
FEV
1
: GOLD I (FEV
1
 $80%), GOLD II (FEV
1
 $50% 
and ,80%) were considered as mild to moderate, while 
GOLD III (FEV
1
 $30% and ,50%) and GOLD IV 
(FEV
1
 ,30%) were considered as severe.1 COPD patients 
Table 1 Demographic, functional, and treatment characteristics 
of healthy subjects and COPD patients
Characteristics Healthy 
subjects (n=35)
COPD patients 
(n=51)
age (years) 57±9 62±10*
sex, M/F 14/21 33/18
height (cm) 169±8 169±10
Weight (kg) 74±12 70±18
BMI (kg/m2) 26±3 24±5
Tobacco status (ns/exs/Cs) 14/0/8 0/26/25
Pack-year 5 (0–42) 44*** (10–125)
FenO (ppb) 18 (6–39) 13* (5–88)
FeV1 pre (ml) 2,986±763 1,517±630***
FeV1 pre (% pred) 106±14 54±18***
FeV1 post (ml) 3,199±885 1,658±701***
FeV1 post (%) 113±15 59±20***
reversibility (%) 3±3 9±9**
FVC pre (ml) 3,799±968 2,796±924***
FVC pre (%) 111±14 79±19***
FVC post (ml) 3,807±1,113 2,951±990**
FVC post (%) 111±15 84±20***
FeV1/FVC pre (%) 79±4 53±10***
FeV1/FVC post (%) 84±4 55±10***
Oral corticosteroids 0 (0%) 6 (12%)
Inhaled corticosteroids 0 (0%) 33 (65%)
Inhaled corticosteroids 
(eg, beclomethasone/day)
0 550*** (0–4,000)
laBa 0 (0%) 39 (77%)
anticholinergics 0 (0%) 29 (57%)
CaT total score – 21 (9–34)
Notes: Data are presented as absolute number, absolute number (percentage), 
mean ± sD, or median (range). *P,0.05, **P,0.01, ***P,0.001 vs healthy subjects.
Abbreviations: BMI, body mass index; ns, nonsmoker; exs, ex-smoker; Cs, current 
smoker; FenO, fractional exhaled nitric oxide; FeV1, forced expiratory volume in 1 
second; FVC, forced vital capacity; pred, predicted; laBa, long-acting beta-agonist; 
CaT, COPD assessment test; sD, standard deviation; M, male; F, female.
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were also classified according to the combined CAT, which 
takes into account symptoms, spirometric classification, and 
risk of exacerbations. Patients were divided in four groups: 
A (low risk and less symptoms), B (low risk and more symp-
toms), C (high risk and less symptoms), and D (high risk 
and more symptoms).1 Based on sputum cellularity, patients 
were classified as neutrophilic phenotype when sputum 
neutrophil count was $76% of sputum total nonsquamous 
cells.22 All the COPD patients included in this study were in 
stable state on the day of sputum sampling as none were 
prescribed antibiotics or methylprednisolone following the 
visit. In addition, the last exacerbation had occurred more 
than 4 weeks prior to the visit.
Healthy subjects were recruited by local advertisement in 
the hospital. None of them exhibited respiratory symptoms 
or airways responsiveness (provocative concentration of 
methacholine causing a fall in FEV
1
 of 20%.16 mg/mL) 
and all had normal spirometric results (FEV
1
 .80% pre-
dicted value).
The study was approved by the CHU Liege Ethics Com-
mittee (ref 2005/181) and all subjects signed an informed 
consent.
sputum induction and processing
Sputum was induced and processed as previously reported.23 
Cell viability was checked by trypan blue exclusion assay and 
the differential cell count was performed on cytospins stained 
with RAPI DIFF II® stain kit (Atom Scientific, Manchester, 
UK) for 500 total nonsquamous cells counted. Only sputum 
samples with ,30% squamous cell count were considered 
suitable for this study. Collected cells were centrifuged 
and the pellet (1–2×106 cells) was mixed with 400 µL of 
RNAprotect® cell reagent (Qiagen, Hilden, Germany) and 
kept at -80°C until RNA extraction.
rna extraction/isolation and cDna 
synthesis
After removing RNAprotect cell reagent (Qiagen), the pellet 
was resuspended in 500 µL of TriPure isolation reagent 
(Roche Diagnostics GmbH, Mannheim, Germany), to which 
was added one stainless steel bead (5 mm, Qiagen). The 
sample was disrupted and homogenized using a TissueLyser 
system (TissueLyser II; Qiagen), for 2 minutes at 25 Hz. 
The RNA was separated by phenol-chloroform extraction. 
The upper aqueous phase (300 µL) was diluted with equal 
volume of ethanol and transferred to a NucleoSpin RNA 
binding column (Macherey-Nagel GmbH & Co., Düren, 
Germany). Washing and drying of silica membrane and 
RNA elution were executed according to NucleoSpin RNA 
clean-up protocol (Macherey-Nagel). The residual genomic 
DNA was eliminated by a DNase treatment with TURBO 
DNA-free™ Kit of Ambion (Thermo Fisher Scientific, 
Waltham, MA, USA). The RNA concentration and purity 
were assessed by NanoDrop ND-1000 spectrophotometer. 
The cDNA was prepared according to the manufacturer’s 
instructions from maximum 1 µg of RNA using QuantiTect® 
Reverse Transcription Kit from Qiagen.
TaqMan real-time qPCr
Quantitative polymerase chain reaction (qPCR) was per-
formed with a 384-well plate (MicroAmp®Optical, Life 
Technologies Holdings Pte Ltd, Singapore) on a 7900HT 
system (Thermo Fisher Scientific) using the QuantiTect® 
Probe PCR Kit (Qiagen). The real-time reaction mixture was 
prepared in a total volume of 10 µL total PCR reaction and 
1 µL cDNA. The cycle parameters were as follows: initial 
enzyme activation at 95°C for 15 minutes; followed by 40 
cycles of sequential incubations at 94°C for 15 seconds and at 
60°C for 1 minute; and one cycle at 40°C for 30 seconds.
Primer pairs and probes, all FAM-TAMRA labeled, were 
selected according to the description of Gielen et al for 18S, 
IFN-β, MxA, OAS, and viperin.24 For IL-29, probe: 5′-AG
TTGCAGCTCTCCTGTCTTCCCCG-3′, forward primer: 
5′-CCTTGGAAGAGTCACTCAAGCT-3′, and reverse primer: 
5′-AGAAGCCTCAGGTCCCAATT-3′ (accession number: 
NM_172140.1) were purchased from Eurogentec (Seraing, 
Belgium). For each sample, a supplementary PCR from RNA 
for IL-29 and IFN-β was performed to verify the absence of 
residual genomic DNA. Copy numbers of each gene were 
determined via standard curves constructed as dsDNA plasmids, 
and normalized with the housekeeping gene 18S rRNA.
Detection of picornavirus
Qualitative PCR was performed in a volume of 50 µL total 
PCR reaction and 4 µL cDNA using GoTaq® G2 Flexi DNA 
Polymerase from Promega Corporation (Fitchburg, WI, 
USA). The cycle parameters were as follows (2720 Thermal 
Cycler from Thermo Fisher Scientific): initial enzyme activa-
tion at 94°C for 2 minutes; followed by 32 cycles of sequential 
incubations at 94°C for 30 seconds, at 50°C for 30 seconds, 
and at 72°C for 2 minutes; and finally one cycle at 72°C for 
4 minutes. The primers used were OL26 and OL27 from 
Thermo Fisher Scientific at 1.5 mM each (product size 380 
base pairs).25 PCR products were fractionated on 1.5% agarose 
(Thermo Fisher Scientific) gels and visualized by ethidium 
bromide staining and photographed. Any visible band of 
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appropriate size was taken as a positive result. Differentiation 
of rhinoviruses from enteroviruses is achieved by restriction 
enzyme digestion of the PCR product. Amplicons generated 
were digested with Bgl-I from Promega Corporation (10 µL 
of PCR product plus 10 µL of Bgl-I mix) at 37°C for 1 hour 
(2720 Thermal Cycler from Thermo Fisher Scientific). PCR 
products were fractionated on 2.5% agarose (Thermo Fisher 
Scientific) gels and visualized by ethidium bromide staining 
and photographed. Any visible single band of appropriate 
size (189 base pairs) was taken as a positive result for human 
rhinovirus. Either not digested (product size 380 base pairs) 
or presenting a double band pattern was taken as a positive 
result for other picornaviruses.
sputum bacteriology 
Sputum samples were collected in sterile sputum cups and 
sent to the laboratory within 1 hour after expectoration. 
The bacterial analysis was performed at the Department 
of Clinical Microbiology, University Hospital of Liège, 
Belgium. A Gram stain of the sputum in the area of maximal 
purulence was examined for polymorphonuclear leukocytes, 
epithelial cells, bacteria, and fungi. Another portion of the 
sputum was used for microbiological analysis. Sputa were 
processed according to the standard microbiological methods. 
Cultures were made on routine media used for the isolation 
of respiratory pathogens, including blood agar, Mac Conkey 
agar, colistin nalidixic acid (CNA) agar, Haemophilus influ-
enzae agar, and Sabouraud agar. The plates were incubated 
at 35°C±2°C in the atmosphere of 5% CO
2
 except for Mac 
Conkey and Sabouraud agars that were incubated in an O
2
 
atmosphere. After 24 and 48 hours of incubation, the plates 
were studied by standard techniques and bacterial colonies 
were identified by mass spectrometry (Matrix-Assisted Laser 
Desorption/Ionization Time-of-Flight mass spectrometry 
[MALDI-TOF]) or phenotypical tests. Respiratory pathogens 
were reported in a semiquantitative manner and subjected 
to antibiotic susceptibility testing performed by automated 
method (VITEK®2; BioMérieux, Marcy l’Etoile, France) or 
by disc diffusion methods.
statistical analysis
Data were analyzed using a statistical software package 
(GraphPad Prism, Version 5). Results were expressed as 
median (range) for nonparametric data and as mean (± standard 
deviation) for parametric data. Comparisons between groups 
for qualitative data were performed by Fisher’s exact test. 
As for quantitative data, groups were compared by Mann–
Whitney for pairwise comparisons or by Kruskal–Wallis with 
post hoc Dunn’s test for multiple comparisons. Spearman’s 
rank correlation coefficient was used to identify relationship 
between variables that showed nonparametric distribution. 
P-values ,0.05 were considered statistically significant.
Results
Patient characteristics
The demographic, functional, and treatment characteristics 
of subjects are given in Table 1. Healthy subjects and COPD 
patients were relatively well age–matched even if COPD 
patients were slightly older. In COPD patients, FEV
1
/FVC 
ratio was inversely correlated with age (r=-0.284; P,0.05). 
The majority of COPD patients (65%) were receiving inhaled 
corticoids (ICS). Blood cell counts of the patients show raised 
numbers of circulating neutrophils and monocytes compared to 
healthy subjects. Likewise, COPD patients had a slight increase 
in fibrinogen and CRP levels, even if the value remained in the 
normal range in the large majority of the patients (Table 2). The 
sputum cell counts are shown in Table 3. COPD patients had 
higher total nonsquamous sputum cell counts and percentage 
Table 2 Peripheral blood cell counts and inflammation parameters of healthy subjects and COPD patients
Blood cells and biomarkers Healthy subjects (n=35) COPD patients (n=51)
Total leukocytes (×103/µl) 6.2 (4.5–9.4) 8.2*** (3.6–17.8)
neutrophils (%) 53.3 (33.9–66) 59.0** (37.3–93.7)
lymphocytes (%) 36.1 (24.2–55.4) 27.3*** (4.5–46.4)
Monocytes (%) 8.0 (4.3–15.3) 8.0 (0.8–13.2)
eosinophils (%) 2.0 (0.5–8.9) 2.2 (0–9.1)
Basophils (%) 0.5 (0.2–1.2) 0.5 (0–1.6)
neutrophils (per mm³) 3,127 (4–18,659) 4,791*** (2,305–15,252)
lymphocytes (per mm³) 2,211 (1,250–4,266) 2,245 (491–3,799)
Monocytes (per mm³) 504 (249–848) 680** (68–1,443)
eosinophils (per mm³) 114 (28–510) 168 (0–569)
Basophils (per mm³) 31 (9–263) 36 (0–89)
Fibrinogen (g/l) 2.9 (2.0–4.4) 3.5*** (2.3–7.0)
C-reactive protein (mg/l) 1.1 (0–6.2) 3.4*** (0–122.2)
Notes: Data are presented as median (range). **P,0.01, ***P,0.001 vs healthy subjects.
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of neutrophils and eosinophils but lower percentage of 
macrophages compared to healthy subjects.
Detection of IFns and Isgs in COPD 
patients
Expression of IL-29 was positive in 16 of 51 COPD patients 
(31%) and in nine of 35 healthy subjects (26%) (P.0.05). 
IFN-β was detected in six of 51 COPD patients (12%) and 
in two of 35 healthy subjects (6%) (P.0.05) (Figure 1A). 
ISGs were readily detectable in both healthy subjects and 
COPD patients. OAS expression was decreased in COPD 
compared to healthy subjects (P,0.05), while that of viperin 
was increased (P,0.01). There was no difference in MxA 
expression between the two groups (Figure 1B).
effect of smoking and inhaled 
corticosteroids
Among the COPD patients and healthy subjects, no differ-
ence was seen in the expression of IL-29 or IFN-β among 
nonsmokers, ex-smokers, and current smokers. Likewise, 
current and ex-smoking habit did not influence OAS and 
MxA expression among the COPD or healthy subjects. 
Viperin expression in healthy smokers was decreased when 
compared to healthy nonsmokers (P,0.05), but no such dif-
ference was seen between COPD smokers and ex-smokers 
(P.0.05). There was no significant difference between the 
COPD patients treated with ICS and those without treatment 
regarding IFNs and ISGs (P.0.05).
relationship between IFns, Isgs, and 
airway obstruction severity
When classified according to the severity of airway obstruction, 
there were no differences in IL-29 or IFN-β expressions between 
the groups (Table 4). However, severe COPD patients showed 
decreased OAS expression compared to healthy subjects 
(P,0.01), whereas mild to moderate COPD patients expressed 
greater level of viperin than healthy subjects (P,0.01). In addi-
tion, MxA and OAS expression positively correlated with post-
bronchodilator FEV
1
/FVC ratio in COPD patients (r=0.328; 
P=0.019 and r=0.341; P=0.014, respectively).
Table 3 sputum weight and cell counts of healthy subjects and COPD patients
Sputum cells Healthy subjects (n=35) COPD patients (n=51)
sputum weight (g) 3 (1–10) 2*** (0–10)
Total nonsquamous cells (×106/g) 1 (0–12) 4*** (0–164)
squamous cells (%) 17 (0–31) 7* (0–68)
Viability (%) 77 (45–95) 72 (46–100)
Macrophages (%) 33 (2–66) 12*** (1–45)
Macrophages (×103/g) 244 (0–1,157) 458* (0–4,523)
lymphocytes (%) 2 (0–6) 1 (0–7)
lymphocytes (×103/g) 14 (0–417) 37* (0–556)
neutrophils (%) 63 (19–96) 76* (11–99)
neutrophils (×103/g) 491 (0–10,037) 2,563*** (253–162,162)
eosinophils (%) 0 (0–11) 2*** (0–78)
eosinophils (×103/g) 2 (0–371) 53*** (0–8,455)
epithelial cells (%) 2 (0–14) 2 (0–30)
epithelial cells (×103/g) 18 (0–180) 70** (0–1,709)
Notes: Data are presented as median (range). *P,0.05, **P,0.01, ***P,0.001 vs healthy subjects.
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Figure 1 expression of interferons and interferon-stimulated genes in healthy subjects and COPD patients.
Notes: expression of (A) interferons and (B) interferon-stimulated genes in healthy subjects and COPD patients. lines represent median. Open symbols represent healthy 
subjects and closed symbols represent COPD patients. *P,0.05, **P,0.01 vs healthy subjects.
Abbreviations: IL-29, interferon lambda1; IFN-β, interferon beta.
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relationship between IFns, Isgs, and 
COPD exacerbations
COPD patients were classified according to the number of 
exacerbations during the last 12 months recorded by history 
taking. When compared to healthy subjects, COPD patients 
with less than two exacerbations displayed higher viperin 
expression while the group that had $2 exacerbations showed 
decreased OAS expression (Table 5).
IFns and Isgs according to aBCD 
gOlD groups
Among the 45 patients with CAT score, the distribution 
of COPD patients in ABCD groups was 1, 27, 0, and 17, 
respectively. Therefore, we only compared healthy subjects, 
and B and D groups. There was no difference with respect to 
IFN-β and IL-29 expression between the groups (Figure 2A). 
By contrast, we found a decrease in all three ISGs in patients 
from group D as compared to group B (P,0.01 for MxA, 
P,0.05 for OAS, and P,0.01 for viperin) (Figure 2B). 
OAS expression in group D was also decreased compared 
to healthy subjects, and viperin expression in group B was 
significantly higher when compared to healthy controls.
relationship between IFns, Isgs, and 
COPD sputum cell counts
IL-29 and IFN-β expressions positively correlated with the 
percentage of sputum neutrophils in COPD patients (r=0.30 
and 0.29, respectively, P,0.05 for both). By contrast, IL-29 
and IFN-β negatively correlated with the percentage of 
sputum macrophages in COPD patients (r=-0.31, P,0.05 
and r=-0.40, P,0.01, respectively). MxA expression was 
inversely related to the percentage of bronchial epithelial 
cells (r=0.29, P,0.05).
relationship between IFns, Isgs, and 
sputum bacteriology
Bacterial culture was performed for the sputum samples of 
39 COPD patients to identify colonization with potential 
pathogenic microorganisms (PPM). Seven out of 39 subjects 
(18%) had positive bacteriology despite being in stable state. 
Among them, three (8%) were positive for Pseudomonas 
aeruginosa, two (5%) for H. influenza, and two (5%) for 
Streptococcus pneumoniae. Sputum neutrophil counts were 
significantly higher when sputum was positive for PPM 
compared to when without PPM (median of 97%, ranging 
from 62% to 99% vs median of 76%, ranging from 11% to 
95%, P,0.05). Positive bacteriology was not associated with 
raised IFNs or ISGs expression (data not shown).
relationship between IFns and Isgs 
and detection of picornavirus in sputum 
samples
The detection of picornaviruses was performed by reverse 
transcription q-PCR (RT-qPCR) in all COPD patients 
Table 4 expression of interferons and interferon-stimulated genes according to airway obstruction in healthy subjects and COPD 
patients
Genes Healthy subjects (n=35) Mild to moderate COPD (n=36) Severe COPD (n=15) P-value
IL-29 0 (0–256) 0 (0–391) 0 (0–435) 0.651
IFN-β 0 (0–56) 0 (0–263) 0 (0–557) 0.330
MxA 9,979 (1,572–27,126) 10,401 (1,171–68,816) 6,742 (0–26,672) 0.061
OAS 960 (0–2,393) 646 (0–3,072) 459** (0–777) 0.004
Viperin 444 (0–2,163) 926** (0–68,346) 598 (0–19,218) 0.006
Notes: Data are presented as median (range) copy number per µl of cDna for each gene of interest. Mild to moderate COPD: post-bronchodilation FeV1 $50% predicted. 
severe COPD: post-bronchodilation FeV1 ,50% predicted. P-values indicate Kruskall–Wallis test; **P,0.01 vs healthy subjects.
Abbreviations: FeV1, forced expiratory volume in 1 second; IL-29, interferon lambda1; IFN-β, interferon beta.
Table 5 expression of interferons and interferon-stimulated genes according to exacerbation number during the last 12 months
Genes Healthy subjects (n=35) COPD ,2 exacerbations (n=40) COPD $2 exacerbations (n=10) P-value
IL-29 0 (0–256) 0 (0–435) 0 (0–242) 0.633
IFN-β 0 (0–56) 0 (0–557) 0 (0–131) 0.270
MxA 9,979 (1,572–27,126) 9,320 (1,489–68,816) 5,022 (0–26,672) 0.100
OAS 960 (0–2,393) 646 (0–3,072) 423** (0–900) 0.006
Viperin 444 (0–2,163) 857** (0–68,346) 362 (0–19,218) 0.002
Notes: Data are presented as median (range) copy number per µl of cDna for each gene of interest. P-values indicate Kruskall–Wallis test; **P,0.01 vs healthy subjects.
Abbreviations: IL-29, interferon lambda1; IFN-β, interferon beta.
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(n=51) and healthy subjects, apart from two healthy subjects 
(n=33). Only 12 sputum samples out of 84 were positive 
for picornaviruses (14%), including eight COPD patients 
(16%) and four healthy subjects (12%). Human rhinovirus 
was detected in seven COPD and one healthy subject, while 
other picornaviruses were detected in one COPD and three 
healthy subjects. Only one COPD patient had concomitant 
detection of both rhinovirus and PPM. Sputum neutrophil 
count was significantly higher in samples positive for picor-
navirus compared to those without virus detection (median of 
87%, ranging from 54% to 97% vs median of 74%, ranging 
from 11% to 99%, P,0.05). Similarly, positive samples for 
PPM and/or picornavirus had significantly higher sputum 
neutrophils when compared to negative samples (median of 
87%, ranging from 54% to 99% vs median of 64%, ranging 
from 11% to 95%, P,0.001). There was no difference in 
IFNs and ISGs between those positive vs negative for viruses 
(data not shown). However, there was a trend to have more 
often detectable IFN-β in those patients positive to either 
picornaviruses or PPM (4/18 vs 4/66; P=0.06).
relationship between IFns, Isgs, and 
systemic inflammation
CRP and fibrinogen levels were in the normal range for the 
majority of COPD patients. Only 15 and 13 COPD patients 
had CRP and fibrinogen above the upper limit of the normal 
range (.6 mg/L and .4.3 g/L, respectively). There was no 
correlation between fibrinogen or CRP levels and IFNs or 
ISGs expression (P.0.05, data not shown). In addition, there 
was no difference in the level of fibrinogen or CRP in the 
blood between positive and negative samples for virus and/or 
bacteria in sputum samples (P.0.05, data not shown).
Discussion
The purpose of our study was to investigate some components 
of the innate immune response in airways from stable COPD 
patients. It appeared that ISGs were expressed to a greater 
extent than IFN-β and IL-29 in both COPD and healthy 
subjects. While ISGs were expressed in almost all subjects, 
IFNs were detected in less than one-third of the patients and 
healthy subjects alike. Our study shows that COPD patients 
had altered IFN-induced gene expression in their sputum 
compared to healthy subjects. The altered expression was 
inconsistent for the whole group with decreased OAS but 
increased viperin and MxA. However, the most severe 
patients, classified as group D according to the GOLD 2015 
guidelines, had clearly reduced ISGs expression compared to 
those from group B. On the other hand, COPD patients with 
the most intense airway neutrophilic inflammation had raised 
expression of IL-29 and IFN-β, the latter being more often 
expressed when microbes were detected in sputum samples.
Our data showed that several ISGs may be differently 
activated. Interestingly, when considering the most severe 
COPD patients from group D of GOLD, it turned out that 
all three ISGs were clearly reduced as compared to mild to 
moderate COPD and also compared to healthy subjects for 
OAS. In addition, the reduction of OAS expression was con-
sistent when considering the most severe COPD, with regard 
to airflow limitation, number of exacerbations in the last 
12 months, and the combined assessment in ABCD groups 
when compared to healthy subjects. The reduced OAS 
expression is in keeping with recently published data from 
the ECLIPSE study where a decreased expression of OASL, 
another member of OAS family, was found by microarray 
analysis in sputum samples from COPD patients prone to 
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Figure 2 expression of interferons and interferon-stimulated genes according to the combined assessment (gOlD 2015).
Notes: expression of (A) interferons and (B) interferon-stimulated genes according to the combined assessment using symptoms, spirometric classification, and risk of 
exacerbations (gOlD 2015). lines represent median. Open symbols represent healthy subjects and closed symbols represent COPD patients from group B (diamonds) and 
group D (triangles). *P,0.05, **P,0.01, ***P,0.001.
Abbreviations: gOlD, global Initiative for Chronic Obstructive lung Disease; IL-29, interferon lambda1; IFN-β, interferon beta.
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exacerbations.26 Zheng et al showed that there was increased 
viral replication in primary airway epithelial cells from 
patients with cystic fibrosis (CF-AECs) caused by the lack 
of NOS2 and OAS induction in response to virus or IFN-γ.27 
They also suggest that the cause of this event is possibly an 
impairment of activation of STAT 1 in CF-AECs compared 
to healthy airway epithelial cells. In our study, it is worth 
noting that viperin seems to be particularly overexpressed 
in mild to moderate COPD while decreased when disease 
becomes more severe and prone to exacerbate. This finding 
is intriguing and may indicate vigorous immune defense 
mechanisms in mild to moderate COPD that diminishes 
when disease progresses. On the other hand, it is worth 
emphasizing that MxA, OAS, and viperin act at different 
successive steps of the intracellular viral cycle. MxA rep-
resents the first line of defense against viral infection inside 
the cell. It forms oligomers that can bind viral components 
and degrade them at early time points of the viral cycle. 
The low constitutive expression levels of OAS are ampli-
fied by IFNs and can detect viral double-stranded RNAs 
(dsRNA).19 After activation by dsRNA, OAS oligomerizes 
and synthesizes 2′,5′-oligoadenylates that activate RNaseL. 
Dimers of RNaseL can then cleave viral and cellular RNA 
in the cytoplasm.19 Viperin might exert its antiviral activity 
by blocking viral budding from lipid rafts as well as by 
inhibiting the formation of viral replication complex in lipid 
droplets, acting overall in later stages of the viral cycle inside 
the cell.20 Combined reduced expression of all these three 
ISGs might strongly weaken the antiviral mechanisms in the 
most severe COPD. Indeed, Hurst et al demonstrated that 
COPD patients with more exacerbations had more frequent 
episodes of naturally occurring colds as compared to patients 
with infrequent exacerbations.28
Further highlighting the link between COPD severity and 
ISGs, our results also show that MxA and OAS expressions 
are directly correlated with post-bronchodilator FEV
1
/FVC 
ratio, thereby demonstrating that expression of ISGs dimin-
ishes as airway obstruction progresses.
The reasons why severe COPD patients have reduced 
ISGs gene expression remain unclear. Although ICS are 
powerful drugs to reduce immune system activation, our 
cross-sectional study does not provide evidence for an impact 
of ICS on IFNs and ISGs expression. A definitive answer to 
this question would, however, require a longitudinal inter-
vention study. Likewise, we did not find an effect of active 
smoking on the gene expression. By contrast, it seems that 
the presence of either picornaviruses or PPM, besides being 
associated with intense sputum neutrophilia, favors IFN-β 
expression (P=0.06).
When combining PPM and picornaviruses, we found 
that approximately one-third of our patients had pathogens 
detected and those patients had raised sputum neutrophil 
counts. It is worth noting that all patients were in stable 
state and had overall CRP and fibrinogen levels in the 
normal range as opposed to what happens during an exac-
erbation.29 The minority of patients with raised CRP and 
fibrinogen levels showed no differences in the expression 
of IFNs and ISGs in sputum cells. This finding points to 
the possibility of other causes of systemic inflammation 
than microbial airways contamination. Although the pres-
ence of microbes in the airways was associated with high 
sputum neutrophil counts, some subjects had very high 
sputum neutrophil counts without evidence of bacterial 
colonization with PPM or infection with picornaviruses. 
Even if conventional bacterial culture lacks sensitivity to 
assess airway bacterial load,30 this might also be seen as 
reflecting innate immune activation following exposure to 
a wide range of irritants, including smokes,10,31 chemical 
dusts, or air pollutants.32–34
One limitation of our study is its cross-sectional design 
precluding any conclusion as to whether the deficiency in 
ISGs found in severe COPD is a phenomenon that is stable 
over time and if this may persist when patients exacerbate 
making infection clearance more difficult.
Conclusion
We conclude that ISGs may be readily detected in stable 
COPD and healthy subjects, while expression of IFNs was 
less clear. ISGs expression was reduced in COPD patients 
prone to exacerbation and with severe airway obstruction. 
The reduced innate immunity in COPD may contribute to 
disease progress by altering response to infection.
Acknowledgments
The authors thank the clinical microbiology laboratory at 
the Centre Hospitalier Universitaire (University of Liege, 
Belgium), Unilab, for the bacteriology tests in sputum. The 
work was supported by federal research grant IAP P7/30.
Author contributions
CH participated in the design of the study, carried out 
RT-qPCR and FACS studies, performed the statistical 
analysis, and drafted the manuscript. JDS participated in the 
design of the study and helped to draft the manuscript. MH 
participated in subjects’ recruitment, RT-qPCR, and FACS 
International Journal of COPD 2016:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1493
reduced sputum Isgs in severe COPD
studies. FS and JLC participated in subjects’ recruitment, 
analysis, and interpretation of data. TK carried out picorna-
viruses study. MRE, PM, SLJ, and RL conceived the study, 
participated in its design and coordination and helped to draft 
the manuscript. All authors read and approved the final manu-
script. All authors contributed toward data analysis, drafting 
and critically revising the paper and agree to be accountable 
for all aspects of the work.
Disclosure
SLJ is an author of patents relating to the use of inhaled 
IFNs as treatments for exacerbations of airway disease. SLJ 
has research grants and/or has consulted for GlaxoSmith-
Kline, Astrazeneca, Merck, Boehinger Ingelheim, Centocor, 
Amgen, Roche/Genentech, Biota, Kyorin, Novartis, Sanofi, 
and Synairgen. RL has research grants and/or has con-
sulted for GlaxoSmithKline, Astrazeneca, Novartis, and 
Chiesi. The other authors report no conflicts of interest in 
this work.
References
 1. From the Global Strategy for the Diagnosis, Management and 
Prevention of COPD, Global Initiative for Chronic Obstructive Lung 
Disease (GOLD); 2015. Available from: http://www.goldcopd.org/. 
Accessed April 7, 2015.
 2. Mathers CD, Loncar D. Projections of global mortality and burden of 
disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.
 3. Beasley V, Joshi PV, Singanayagam A, Molyneaux PL, Johnston SL, 
Mallia P. Lung microbiology and exacerbations in COPD. Int J Chron 
Obstruct Pulmon Dis. 2012;7:555–569.
 4. Sethi S, Murphy TF. Infection in the pathogenesis and course of 
chronic obstructive pulmonary disease. N Engl J Med. 2008;359(22): 
2355–2365.
 5. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflam-
mation in chronic obstructive pulmonary disease severe exacerbations. 
Am J Respir Crit Care Med. 2006;173(10):1114–1121.
 6. Perotin JM, Dury S, Renois F, et al. Detection of multiple viral and bac-
terial infections in acute exacerbation of chronic obstructive pulmonary 
disease: a pilot prospective study. J Med Virol. 2013;85(5):866–873.
 7. Caramori G, Kirkham P, Barczyk A, Di Stefano A, Adcock I. Molecular 
pathogenesis of cigarette smoking-induced stable COPD. Ann N Y Acad Sci. 
2015;1340:55–64.
 8. Baines KJ, Hsu AC, Tooze M, Gunawardhana LP, Gibson PG, Wark PA. 
Novel immune genes associated with excessive inflammatory and anti-
viral responses to rhinovirus in COPD. Respir Res. 2013;14:15.
 9. Baines KJ, Simpson JL, Gibson PG. Innate immune responses are 
increased in chronic obstructive pulmonary disease. PLoS One. 2011; 
6(3):e18426.
 10. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in 
interleukin-8 and tumor necrosis factor-alpha in induced sputum from 
patients with chronic obstructive pulmonary disease or asthma. Am J 
Respir Crit Care Med. 1996;153(2):530–534.
 11. Moermans C, Bonnet C, Willems E, et al. Sputum cytokine levels 
in patients undergoing hematopoietic SCT and comparison with 
healthy subjects and COPD: a pilot study. Bone Marrow Transplant. 
2014;49(11):1382–1388.
 12. Zhang X, Zheng H, Zhang H, et al. Increased interleukin (IL)-8 and 
decreased IL-17 production in chronic obstructive pulmonary disease 
(COPD) provoked by cigarette smoke. Cytokine. 2011;56(3):717–725.
 13. Nadigel J, Audusseau S, Baglole CJ, Eidelman DH, Hamid Q. IL-8 
production in response to cigarette smoke is decreased in epithelial cells 
from COPD patients. Pulm Pharmacol Ther. 2013;26(5):596–602.
 14. Berenson CS, Kruzel RL, Eberhardt E, et al. Impaired innate immune 
alveolar macrophage response and the predilection for COPD exacerba-
tions. Thorax. 2014;69(9):811–818.
 15. Mallia P, Message SD, Gielen V, et al. Experimental rhinovirus infection 
as a human model of chronic obstructive pulmonary disease exacerba-
tion. Am J Respir Crit Care Med. 2011;183(6):734–742.
 16. Contoli M, Message SD, Laza-Stanca V, et al. Role of deficient type III 
interferon-lambda production in asthma exacerbations. Nat Med. 2006; 
12(9):1023–1026.
 17. Edwards MR, Slater L, Johnston SL. Signalling pathways mediating type I 
interferon gene expression. Microbes Infect. 2007;9(11):1245–1251.
 18. Singanayagam A, Joshi PV, Mallia P, Johnston SL. Viruses exacerbat-
ing chronic pulmonary disease: the role of immune modulation. BMC 
Med. 2012;10:27.
 19. Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat 
Rev Immunol. 2008;8(7):559–568.
 20. Mattijssen S, Pruijn GJ. Viperin, a key player in the antiviral response. 
Microbes Infect. 2012;14(5):419–426.
 21. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy 
N. Development and first validation of the COPD Assessment Test. 
Eur Respir J. 2009;34(3):648–654.
 22. Schleich FN, Manise M, Sele J, Henket M, Seidel L, Louis R. Distribu-
tion of sputum cellular phenotype in a large asthma cohort: predicting 
factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med. 
2013;13:11.
 23. Quaedvlieg V, Sele J, Henket M, Louis R. Association between asthma 
control and bronchial hyperresponsiveness and airways inflammation: 
a cross-sectional study in daily practice. Clin Exp Allergy. 2009;39(12): 
1822–1829.
 24. Gielen V, Johnston SL, Edwards MR. Azithromycin induces anti-
viral responses in bronchial epithelial cells. Eur Respir J. 2010;36(3): 
646–654.
 25. Papadopoulos NG, Hunter J, Sanderson G, Meyer J, Johnston SL. 
Rhinovirus identification by BglI digestion of picornavirus RT-PCR 
amplicons. J Virol Methods. 1999;80(2):179–185.
 26. Singh D, Fox SM, Tal-Singer R, Bates S, Riley JH, Celli B. Altered 
gene expression in blood and sputum in COPD frequent exacerbators 
in the ECLIPSE cohort. PLoS One. 2014;9(9):e107381.
 27. Zheng S, De BP, Choudhary S, et al. Impaired innate host defense 
causes susceptibility to respiratory virus infections in cystic fibrosis. 
Immunity. 2003;18(5):619–630.
 28. Hurst JR, Donaldson GC, Wilkinson TM, Perera WR, Wedzicha JA. 
Epidemiological relationships between the common cold and exacerba-
tion frequency in COPD. Eur Respir J. 2005;26(5):846–852.
 29. Corhay JL, Moermans C, Henket M, Nguyen Dang D, Duysinx B, Louis R. 
Increased of exhaled breath condensate neutrophil chemotaxis in acute 
exacerbation of COPD. Respir Res. 2014;15:115.
 30. Garcha DS, Thurston SJ, Patel AR, et al. Changes in prevalence and 
load of airway bacteria using quantitative PCR in stable and exacerbated 
COPD. Thorax. 2012;67(12):1075–1080.
 31. Doz E, Noulin N, Boichot E, et al. Cigarette smoke-induced pulmonary 
inflammation is TLR4/MyD88 and IL-1R1/MyD88 signaling depen-
dent. J Immunol. 2008;180(2):1169–1178.
 32. Nightingale JA, Rogers DF, Barnes PJ. Effect of inhaled ozone on 
exhaled nitric oxide, pulmonary function, and induced sputum in normal 
and asthmatic subjects. Thorax. 1999;54(12):1061–1069.
 33. Nordenhall C, Pourazar J, Blomberg A, Levin JO, Sandstrom T, Adelroth E. 
Airway inflammation following exposure to diesel exhaust: a study of time 
kinetics using induced sputum. Eur Respir J. 2000;15(6):1046–1051.
 34. Wallace J, D’Silva L, Brannan J, Hargreave FE, Kanaroglou P, Nair P. 
Association between proximity to major roads and sputum cell counts. 
Can Respir J. 2011;18(1):13–18.
International Journal of COPD
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal
The International Journal of COPD is an international, peer-reviewed 
journal of therapeutics and pharmacology focusing on concise rapid 
reporting of clinical studies and reviews in COPD. Special focus is given 
to the pathophysiological processes underlying the disease, intervention 
programs, patient focused education, and self management protocols. 
This journal is indexed on PubMed Central, MedLine and CAS. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
International Journal of COPD 2016:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1494
hilzendeger et al
